



## **ENDOCEUTICS ANNOUNCES ACQUISITION OF THE INTRAROSA® U.S. COMMERCIAL RIGHTS BY MILLICENT PHARMA**

*A new beginning for the first innovative drug in decades for the local treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.*

**Quebec City, Canada, May 27<sup>th</sup>, 2020;** Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals. INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

“Intrarosa has the potential to significantly increase the quality of life of the post-menopausal women and we believe that Millicent together with The Carlyle Group have the expertise and leadership to give this product a fresh start. The management team of Millicent has an impressive track record of successes in the women’s health space and we are looking forward to working with them” commented Dennis Turpin, President and Chief Executive Officer of Endoceutics.

### **About Dyspareunia**

The lack of sex hormones associated with menopause may cause the tissues of the vulva and vagina to become thin and dry. Prasterone is used to make sex hormones in the vagina. This medicine replaces the natural sex hormones that are lacking in some women. It may improve the symptoms of vulvovaginal atrophy such as vaginal dryness, pain during sexual activity (dyspareunia), irritation and itching.

It is estimated that over 50% of postmenopausal women suffer from the symptoms of vulvovaginal atrophy, such as dyspareunia and that less than 10% of these women are treated with prescription medicines.

### **About INTRAROSA®**

INTRAROSA is a vaginal ovule containing 6.5 mg of prasterone. It comes in blister packs of 28 ovules, with 28 reusable applicators. The recommended dose is one vaginal ovule inserted once a day at bedtime, using the provided applicator or fingers.

INTRAROSA is approved for commercialisation in the US, Europe, UK, Canada, and more recently in Hong-Kong, Israel, United Arab Emirates and Switzerland.

### **About Millicent Pharma**

Millicent Pharma is a pharmaceutical company that is focused on improving patient lives and outcomes and seeks to acquire, develop, manufacture, and commercialize pharmaceutical products globally. The executive team at Millicent Pharma – John King, Roger Boissonneault, and Geoffrey Elliot – will seek future

acquisitions with the financial backing of the executive team and The Carlyle Group. Millicent Pharma is headquartered in Ireland.

**About Endoceutics®**

Endoceutics, Inc. is focused on women's health and possesses manufacturing plants and equipment to manufacture drugs, as well as bioanalytical laboratories. Endoceutics has the expertise for clinical development, registration and commercialization of its products and it has a portfolio of drugs at various stages of development. Endoceutics' mission is to provide women the quality of life they deserve.

For more information, please visit [www.endoceutics.com](http://www.endoceutics.com).

**Contact**

[info@endoceutics.com](mailto:info@endoceutics.com)

(418) 653-0033

---